Owaid M Almalki1, Wei-Jei Lee2, Keong Chong3, Kong-Han Ser4, Yi-Chih Lee5, Shu-Chun Chen4. 1. Department of Surgery, Min-Sheng General Hospital, Toayuan City, Taiwan; Department of Surgery, College of Medicine, Taif University, Tai'if, Saudi Arabia. 2. Department of Surgery, Min-Sheng General Hospital, Toayuan City, Taiwan. Electronic address: wjlee_obessurg_tw@yahoo.com.tw. 3. Department of Internal Medicine, Min-Sheng General Hospital, Toayuan City, Taiwan. 4. Department of Surgery, Min-Sheng General Hospital, Toayuan City, Taiwan. 5. Department of International Business, Chien Hsin University of Science and Technology, Toayuan City, Taiwan.
Abstract
BACKGROUND: In recent years, gastric bypass surgery has been found to have therapeutic potential for the treatment of type 2 diabetes (T2D). However, the difference between 2 bypass procedures, Roux-en-Y gastric bypass (RYGB) and another single anastomosis gastric bypass (SAGB), is not clear. OBJECTIVE: To evaluate the differences between SAGB and RYGB in the efficacy of T2D remission in obese patients. SETTING: Tertiary teaching hospital. METHODS: Outcomes of 406 (259 women and 147 male) patients who had undergone RYGB (157) or SAGB (249) for the treatment of T2D with 1-year follow-up were assessed. The remission of T2D after surgery was evaluated in matched groups, including body mass index (BMI) and the ABCD scoring system, which comprises patient age, BMI, C-peptide levels, and duration of T2D (yr). RESULTS: The weight loss of the SAGB patients at 1 year after surgery was better than the RYGB patients (24.1% [8.4%] versus 30.7% [8.7%]; P<.001). The mean BMI decreased from 39.9 (8.0) to 27.4 (4.6) kg/m2 in SAGB patients at 1 year after surgery and decreased from 34.5 (6.6) to 26.2 (4.2) kg/m2 in the RYGB patients. The mean glycated hemoglobin A1C (HbA1C) decreased from 8.6% to 6.2% of the RYGB group and from 8.6% to 5.5% of the SAGB group. Eighty-seven (55.4%) patients of the RYGB group and 204 (81.9%) of the SAGB group achieved complete remission of T2D (HbA1C<6.0%) at 1 year after surgery (P<.001). SAGB exhibited significantly better glycemic control than RYGB surgery in selected groups stratified by different BMI and ABCD score. At 5 years after surgery, SAGB still had a better remission of T2D than RYGB (70.5% versus 39.4%; P = .002). Multivariate analysis confirms that both SAGB and ABCD score are independent predictors of T2D remission after bypass surgery. CONCLUSIONS: Both RYGB and SAGB are effective metabolic surgery. SAGB carries a higher power on T2D remission than RYGB in a small group of patients. ABCD score is useful in T2D patient classification and selection for different procedures.
BACKGROUND: In recent years, gastric bypass surgery has been found to have therapeutic potential for the treatment of type 2 diabetes (T2D). However, the difference between 2 bypass procedures, Roux-en-Y gastric bypass (RYGB) and another single anastomosis gastric bypass (SAGB), is not clear. OBJECTIVE: To evaluate the differences between SAGB and RYGB in the efficacy of T2D remission in obesepatients. SETTING: Tertiary teaching hospital. METHODS: Outcomes of 406 (259 women and 147 male) patients who had undergone RYGB (157) or SAGB (249) for the treatment of T2D with 1-year follow-up were assessed. The remission of T2D after surgery was evaluated in matched groups, including body mass index (BMI) and the ABCD scoring system, which comprises patient age, BMI, C-peptide levels, and duration of T2D (yr). RESULTS: The weight loss of the SAGBpatients at 1 year after surgery was better than the RYGB patients (24.1% [8.4%] versus 30.7% [8.7%]; P<.001). The mean BMI decreased from 39.9 (8.0) to 27.4 (4.6) kg/m2 in SAGBpatients at 1 year after surgery and decreased from 34.5 (6.6) to 26.2 (4.2) kg/m2 in the RYGB patients. The mean glycated hemoglobin A1C (HbA1C) decreased from 8.6% to 6.2% of the RYGB group and from 8.6% to 5.5% of the SAGB group. Eighty-seven (55.4%) patients of the RYGB group and 204 (81.9%) of the SAGB group achieved complete remission of T2D (HbA1C<6.0%) at 1 year after surgery (P<.001). SAGB exhibited significantly better glycemic control than RYGB surgery in selected groups stratified by different BMI and ABCD score. At 5 years after surgery, SAGB still had a better remission of T2D than RYGB (70.5% versus 39.4%; P = .002). Multivariate analysis confirms that both SAGB and ABCD score are independent predictors of T2D remission after bypass surgery. CONCLUSIONS: Both RYGB and SAGB are effective metabolic surgery. SAGB carries a higher power on T2D remission than RYGB in a small group of patients. ABCD score is useful in T2D patient classification and selection for different procedures.
Authors: A van Rijswijk; N van Olst; A S Meijnikman; Y I Z Acherman; S C Bruin; A W van de Laar; C C van Olden; O Aydin; H Borger; U H W Beuers; H Herrema; J Verheij; J A Apers; F Bäckhed; V E A Gerdes; M Nieuwdorp; L M de Brauw Journal: Trials Date: 2022-10-22 Impact factor: 2.728
Authors: Almino C Ramos; Jean-Marc Chevallier; Kamal Mahawar; Wendy Brown; Lilian Kow; Kevin P White; Scott Shikora Journal: Obes Surg Date: 2020-05 Impact factor: 4.129
Authors: Reza A Ashrafi; Aila J Ahola; Milla Rosengård-Bärlund; Tuure Saarinen; Sini Heinonen; Anne Juuti; Pekka Marttinen; Kirsi H Pietiläinen Journal: Ann Med Date: 2021-12 Impact factor: 4.709
Authors: Alexander Dimitri Miras; Anna Kamocka; Belén Pérez-Pevida; Sanjay Purkayastha; Krishna Moorthy; Ameet Patel; Harvinder Chahal; Gary Frost; Paul Bassett; Lidia Castagnetto-Gissey; Lucy Coppin; Nicola Jackson; Anne Margot Umpleby; Stephen Robert Bloom; Tricia Tan; Ahmed Rashid Ahmed; Francesco Rubino Journal: Diabetes Care Date: 2020-11-06 Impact factor: 19.112
Authors: Noyan Gokce; Shakun Karki; Alyssa Dobyns; Elaina Zizza; Emily Sroczynski; Joseph N Palmisano; Celestina Mazzotta; Naomi M Hamburg; Luise I Pernar; Brian Carmine; Cullen O Carter; Michael LaValley; Donald T Hess; Caroline M Apovian; Melissa G Farb Journal: JAMA Netw Open Date: 2021-07-01